Finance

Lists
003220:KRX
Daewon Pharmaceutical Co Ltd
â‚©7,820.00
+0.13%
(+10.00) 1D
Aug 25, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 003220...
Open
â‚©7,810
High
â‚©7,870
Low
â‚©7,680
Mkt. cap
175.38B
Avg. vol.
33.24K
Volume
16.18K
Dividend
3.20%
Quarterly dividend
â‚©63
Ex-dividend date
Dec 29, 2025
P/E ratio
66.75
52-wk high
â‚©13,670
52-wk low
â‚©7,060
EPS
â‚©117
Shares outstanding
22.43M
No. of employees
1K
Open
â‚©7,810
High
â‚©7,870
Low
â‚©7,680
Mkt. cap
175.38B
Avg. vol.
33.24K
Volume
16.18K
Dividend
3.20%
Quarterly dividend
â‚©63
Ex-dividend date
Dec 29, 2025
P/E ratio
66.75
52-wk high
â‚©13,670
52-wk low
â‚©7,060
EPS
â‚©117
Shares outstanding
22.43M
No. of employees
1K
About Daewon Pharmaceutical Co Ltd
CEOJonathan In Baek | Baek Seung-yeol
Employees1.28K
Founded1958
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
143.94B
159.81B
158.06B
152.83B
Cost of goods sold
83.20B
86.55B
83.32B
82.01B
Cost of revenue
83.20B
86.55B
83.32B
82.01B
Research and development expenses
6.44B
6.55B
6.78B
4.84B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
61.82B
58.27B
60.97B
63.81B
Operating expense
71.13B
67.39B
70.35B
70.77B
Total operating expenses
154.33B
153.93B
153.67B
152.79B
Operating income
-10.39B
5.88B
4.38B
43.44M
Other non operating income
-1.24B
-2.49B
127.02M
2.35B
EBT including unusual items
-12.01B
11.79B
3.92B
5.35B
EBT excluding unusual items
-11.95B
2.77B
4.15B
3.31B
Income tax expense
6.02B
-2.45B
1.83B
1.35B
Effective tax rate
-50.14%
-20.77%
46.72%
25.25%
Other operating expenses
890.07M
847.43M
869.07M
818.26M
Net income
-17.41B
13.60B
2.42B
4.03B
Net profit margin
-12.10%
8.51%
1.53%
2.64%
Earnings per share
-
-
-
-
Interest and investment income
150.63M
346.40M
449.07M
307.63M
Interest expense
-1.98B
-1.40B
-1.74B
-1.65B
Net interest expenses
-1.82B
-1.06B
-1.29B
-1.34B
Depreciation and amortization charges
1.15B
1.06B
1.05B
1.08B
EBITDA
-4.51B
11.94B
10.76B
6.31B
Gain or loss from assets sale
-197.23M
1.85B
4.90M
-1.76B
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps